fiercebiotech.com

DNS Records

Cloudflare

Content Delivery Network

Marketo

Customer Relationship Management

Google Webmaster Tools

Analytics

Bootstrap

Web Framework

Tailwind CSS

Web Framework

Vimeo

Videos

Twitter

Social Media

Facebook

Social Media

RSS

Open Web

Services

fiercebiotech

Twitter

fiercebiotech

Facebook

Social media

JSON+LD

{
  "@context": "https://schema.org/",
  "@type": "ItemList",
  "url": "https://www.fiercebiotech.com/fierce-biotech-homepage",
  "numberOfItems": 10,
  "itemListElement": [
    {
      "@type": "ListItem",
      "position": 1,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/research/massive-randomized-trial-rural-china-reveals-lowering-blood-pressure-reduces-dementia-risk",
        "name": "Lowering blood pressure reduces dementia risk in patients with hypertension, large China trial reveals",
        "description": "Patients with hypertension who intensively lowered their blood pressure had reduced risks of dementia and cognitive impairment.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1320153696_0.jpg?VersionId=HzjPqxgopfwyqhxLzV3The0660YBXtrn"
      }
    },
    {
      "@type": "ListItem",
      "position": 2,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/mosaic-adds-cancer-combo-pattern-licensing-2-clinical-stage-drugs-astex",
        "name": "Mosaic adds to cancer combo pattern by licensing 2 clinical-stage drugs from Astex",
        "description": "Mosaic secured the latest pieces in its medicine combination strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex ",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/Mosaic.jpg?VersionId=1WSOvnqkVECSWd4Doxv4wacFYYhvaNQX"
      }
    },
    {
      "@type": "ListItem",
      "position": 3,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/bioxodes-halts-phase-2-stroke-trial-after-successful-interim-review-plots-registrational",
        "name": "Bioxodes halts phase 2 stroke trial after successful interim review, plots registrational study",
        "description": "Bioxodes has stopped enrollment after hitting the safety and efficacy endpoints, positioning it to power into a potentially registrational trial.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1168179082.jpg?VersionId=ircI65xB6ij0H9uiss8ucKEc8C527x74"
      }
    },
    {
      "@type": "ListItem",
      "position": 4,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
        "name": "Fierce Biotech Fundraising Tracker '25: Granite gathers $100M; Etiome emerges with $50M",
        "description": "Welcome to Fierce Biotech's Fundraising Tracker for 2025.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1900824580_0.jpg?VersionId=F0rR5V97Kuh8zRq17bdFNl4EV1lnbfLz"
      }
    },
    {
      "@type": "ListItem",
      "position": 5,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/versants-granite-bio-unveils-100m-new-autoimmune-disease-antibodies",
        "name": "Versant's Granite Bio unveils with $100M for new autoimmune disease antibodies",
        "description": "Granite has raised combined series A and B funds of $100 million, with support from Versant Ventures, Novartis, Forbion and Sanofi.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1262668667.jpg?VersionId=suAtv_y2Go.OU7t0J1br8O6AS0Iinb7z"
      }
    },
    {
      "@type": "ListItem",
      "position": 6,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/research/non-profit-cultivarium-nets-10m-build-tools-researchers-studying-fungi-and-archaea",
        "name": "Nonprofit Cultivarium nets $10M to build tools for researchers studying fungi and archaea",
        "description": "Cultivarium will document how fungi grow under different conditions, develop gene editing tools and connect the research community.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-2162850186.jpg?VersionId=xBzGRS6YQ4uD.c.svJ5JLA1PPkC7ymvB"
      }
    },
    {
      "@type": "ListItem",
      "position": 7,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/etiome-emerges-50-million-flagship-pioneering-and-goal-preempting-disease",
        "name": "Etiome emerges with $50M from Flagship Pioneering and goal of preempting disease",
        "description": "The company combines multiomics data, AI and electronic health records to “build a molecular and cellular journey of disease.\"",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1855196702.jpg?VersionId=lyQMOH85aELsmlKyLi1BEpxNqTE.cQpq"
      }
    },
    {
      "@type": "ListItem",
      "position": 8,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/sanofis-oral-tnf-inhibitor-misses-mark-phase-2-psoriasis-trial-prompting-focus-combos",
        "name": "Sanofi's oral TNF inhibitor misses mark in phase 2 psoriasis trial, prompting focus on combos",
        "description": "Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback, prompting the French drugmaker to pull back from monotherapy plans.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-950674666.jpg?VersionId=E7.0_PlDq_3.Ih.lJlDlQgKY0kZ3gmIe"
      }
    },
    {
      "@type": "ListItem",
      "position": 9,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/biotech/tariffs-will-make-financial-case-pharma-ma-more-difficult-says-roche-ceo",
        "name": "Tariffs will make financial case for pharma M&A 'more difficult,' says Roche CEO",
        "description": "Big Pharma M&A will likely take a hit if the U.S. government lives up to its threats of imposing tariffs on the industry, Roche’s CEO has warned.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/Roche.jpg?VersionId=kmYay4aRQX7_nPirfowbV_J.CGMtiO8C"
      }
    },
    {
      "@type": "ListItem",
      "position": 10,
      "item": {
        "@type": "Article",
        "url": "https://www.fiercebiotech.com/cro/bayer-tunes-precision-oncology-development-concertais-database",
        "name": "Bayer tunes precision oncology development using ConcertAI's database",
        "description": "Bayer will gain access to ConcertAI’s clinical molecular database and AI analysis tools.",
        "image": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-97551599.jpg?VersionId=1cPfpRIyTiKHNT4LwiC5cQtgxPMUE0U1"
      }
    }
  ]
}